07:25 AM EDT, 03/17/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to the company's experimental drug, bexobrutideq, for treating Waldenstrom macroglobulinemia, a type of blood cancer.

The company said the drug is currently being evaluated in a phase 1 trial for adults with relapsed or refractory B-cell malignancies.

The US health agency's orphan drug designation program supports the development of treatments for rare diseases, impacting fewer than 200,000 individuals in the US, the company said.